TY  - JOUR
AU  - Merino-Bohórquez, V
AU  - Docobo-Pérez, F
AU  - Sojo, J
AU  - Morales, I
AU  - Lupión, C
AU  - Martín, D
AU  - Cameán, M
AU  - Hope, W
AU  - Pascual, Á
AU  - Rodríguez-Baño, J
PY  - 2018
DO  - 10.1016/j.cmi.2018.02.005
UR  - http://hdl.handle.net/10668/12339
T2  - Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
AB  - To describe the population pharmacokinetics of fosfomycin for patients with bacteraemic urinary tract infection (BUTI). The analysis identified optimal regimens on the basis of pharmacodynamic targets and assessed the adequacy of Clinical and...
LA  - en
KW  - Fosfomycin
KW  - Mathematical model
KW  - PTA
KW  - Pharmacodynamics
KW  - Pharmacokinetics
KW  - Susceptibility breakpoints
KW  - Aged
KW  - Aged, 80 and over
KW  - Anti-Bacterial Agents
KW  - Computer Simulation
KW  - Dose-Response Relationship, Drug
KW  - Drug Resistance, Multiple, Bacterial
KW  - Escherichia coli Infections
KW  - Female
KW  - Fosfomycin
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Models, Biological
KW  - Monte Carlo Method
KW  - Urinary Tract Infections
KW  - Uropathogenic Escherichia coli
TI  - Population pharmacokinetics and pharmacodynamics of fosfomycin in non-critically ill patients with bacteremic urinary infection caused by multidrug-resistant Escherichia coli.
TY  - research article
VL  - 24
ER  -